The estimated Net Worth of Rodger Novak is at least $66.7 millió dollars as of 30 June 2021. Rodger Novak owns over 25,000 units of CRISPR Therapeutics AG stock worth over $26,037,438 and over the last 8 years he sold CRSP stock worth over $39,968,624. In addition, he makes $645,572 as Chairman of the Board, President és Co-Founder at CRISPR Therapeutics AG.
Sign up
Rodger Novak CRSP stock SEC Form 4 insiders trading
Rodger has made over 30 trades of the CRISPR Therapeutics AG stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 25,000 units of CRSP stock worth $4,125,000 on 30 June 2021.
The largest trade he's ever made was exercising 100,000 units of CRISPR Therapeutics AG stock on 30 November 2020 worth over $1,422,000. On average, Rodger trades about 37,209 units every 46 days since 2016. As of 30 June 2021 he still owns at least 573,007 units of CRISPR Therapeutics AG stock.
You can see the complete history of Rodger Novak stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Rodger Novak biography
Dr. Rodger Novak M.D. serves as Chairman of the Board, President, Co-Founder of the Company. He has served as a director on our Board of Directors since inception, served as our Chief Executive Officer until December 1, 2017 and, since that date, has served as our President and since December 21, 2017 as our Chairman. Prior to joining our company, Dr. Novak served as Global Head Anti-infectives Research and Development at Sanofi, a pharmaceutical company. Prior to Sanofi, Dr. Novak co-founded Nabriva Therapeutics AG, a biopharmaceutical company, in January 2006, and served as its Chief Operating Officer from inception to May 2012. From March 2003 to January 2006, Dr. Novak served as the Deputy Head of the Antibiotic Research Institute at Sandoz GmbH. Dr. Novak was appointed as Professor for Microbiology at the Vienna Biocenter in March 2001. Dr. Novak received an M.D. from Philipps University of Marburg, Germany. He continued with post-doctoral work in New York City at The Rockefeller University, St. Jude Children’s Research Hospital and the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center. Dr. Novak has authored numerous publications, including articles in Nature, Nature Medicine and Molecular Cell and is a co-inventor of five patents. Novak’s experience as our Chief Executive Officer, as well as his experience in the biopharmaceutical industry, qualifies him to serve on our Board of Directors.
What is the salary of Rodger Novak?
As the Chairman of the Board, President és Co-Founder of CRISPR Therapeutics AG, the total compensation of Rodger Novak at CRISPR Therapeutics AG is $645,572. There are 8 executives at CRISPR Therapeutics AG getting paid more, with Samarth Kulkarni having the highest compensation of $16,265,700.
How old is Rodger Novak?
Rodger Novak is 52, he's been the Chairman of the Board, President és Co-Founder of CRISPR Therapeutics AG since 2017. There are 7 older and 8 younger executives at CRISPR Therapeutics AG. The oldest executive at CRISPR Therapeutics AG is Katherine High, 68, who is the Independent Director.
What's Rodger Novak's mailing address?
Rodger's mailing address filed with the SEC is C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET, CAMBRIDGE, MA, 02139.
Insiders trading at CRISPR Therapeutics AG
Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over $284,003,967 worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth $53,410,590 . The most active insiders traders include Plc Gsk, Ali Behbahani és Corp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of $2,405,548. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth $318,080.
What does CRISPR Therapeutics AG do?
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
What does CRISPR Therapeutics AG's logo look like?
Complete history of Rodger Novak stock trades at CRISPR Therapeutics AG
CRISPR Therapeutics AG executives and stock owners
CRISPR Therapeutics AG executives and other stock owners filed with the SEC include:
-
Samarth Kulkarni,
Chief Executive Officer, Director -
Lawrence Klein,
Chief Operating Officer, Chief Business Officer -
Tony Ho,
Executive Vice President - Research and Development -
James Kasinger,
General Counsel, Secretary -
Michael Tomsicek,
Chief Financial Officer -
Dr. Samarth Kulkarni,
CEO & Director -
Dr. Lawrence Otto Klein Ph.D.,
Chief Operating Officer -
James R. Kasinger,
Gen. Counsel & Sec. -
Rodger Novak,
Chairman of the Board, President, Co-Founder -
Dr. Rodger Novak M.D.,
Founder, Chairman & Pres -
Susan Kim,
IR Contact Officer -
Katherine High,
Independent Director -
John Greene,
Independent Director -
Simeon George,
Independent Director -
Bradley Bolzon,
Independent Director -
Ali Behbahani,
Independent Director -
Dr. Daniel G. Anderson Ph.D.,
Scientific Founder & Advisory Board Member -
Dr. Matthew Porteus M.D., Ph.D.,
Scientific Founder & Advisory Board Member -
Dr. Chad Cowan Ph.D.,
Scientific Founder -
Dr. Craig C. Mello Ph.D.,
Scientific Founder & Advisory Board Member -
Dr. Emmanuelle Marie Charpentier,
Co-Founder & Scientific Advisory Board Member -
Shaun Foy,
Founder -
Aktiengesellschaft Bayer Gl...,
-
Tyler Dylan Hyde,
Chief Legal Officer -
Pablo J Cagnoni,
Director -
Venture Capital Iv, L.P.Ver...,
-
Harbor Master Investors (Ca...,
10% owner -
Kurt Von Emster,
Director -
Sven Ante Lundberg,
Chief Scientific Officer -
Corp /De/ Celgene,
10% owner -
Kala Subramanian,
See Remarks -
Thomas Woiwode,
Director -
N Anthony Coles,
Director -
Plc Gsk,
10% owner -
Pharmaceuticals (Europe) Lt...,
-
Venture Capital Iv, L.P.Ver...,
-
Julianne Bruno,
Chief Operating Officer -
Brendan Smith,
Chief Financial Officer -
Venture Capital Iv, L.P.Ver...,
-
Venture Capital V, L.P.Vers...,
-
Naimish Patel,
Chief Medical Officer -
Harold Edward Fleming,
-
Maria Fardis,
-
Sandesh Mahatme,
-
Douglas A Treco,
-
Christian Rommel,
-
Phuong Khanh Morrow,
Chief Medical Officer -
Raju Prasad,
Chief Financial Officer